RNAscope in situ hybridization (ISH) platforms are utilized widely for high resolution tissue-based and cell-specific analysis of targets and biomarkers.  

ACD’s RNAscope ISH platform is clinically validated and enable quantitative expression analysis that has proven repeatedly to better stratify treatment-responsive and non-responsive patients in novel therapeutic clinical trials compared to more established methods, like IHC and qPCR. 

RNAscope is often more sensitive than IHC and provides cell-specific biomarker data in complex tissue microenvironments that qPCR cannot. 

A further advantage is speed. RNAscope biomarker assays can be verified and ready for use on clinical biopsies in a matter of weeks.

• Quantifiable, single-molecule detection of biomarker RNA in fixed biopsies
• Superior performance against established methods, e.g., IHC, qPCR
• Multiplexed analysis for immuno-oncology biomarkers
• Application in small molecule, biologic and cell therapy biomarkers